DUBLIN - ( BUSINESS WIRE ) - Afimmune, a clinical stage company focused on the development of bioactive lipids for the treatment of inflammatory and cardiometabolic diseases, today presented the main results obtained with Epeleuton in a study using a well-established hamster model for SARS-CoV-2 infection. Epeleuton has already demonstrated positive anti-inflammatory and metabolic effects in phase II clinical trials carried out on patients and conducted by the Company.
Afimmune, a clinical stage drug discovery company focused on the development of biologically active lipids for the treatment of cardiometabolic diseases, today announced key findings with epeleuton from preclinical atherosclerosis studies. Epeleuton is a next-generation synthetic n-3 fatty acid, which was shown to have clinically meaningful triglyceride lowering, anti-hyperglycemic and anti-inflammatory effects in a phase 2a clinical trial conducted by Afimmune.